Apr 14, 2023 7:00 am EDT MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
Apr 13, 2023 7:00 am EDT MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary
Dec 01, 2022 7:30 am EST MindMed to Participate in the Canaccord Genuity New Paradigms and Treatment Approaches in Mental Health Conference
Nov 10, 2022 8:05 am EST MindMed Reports Third Quarter 2022 Financial Results and Business Highlights
Nov 03, 2022 7:30 am EDT MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial Results and Provide Business Update